| abstract |
Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R<1> is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR<5>R<6> or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr; R<2> is C1 to C6 alkyl; R<3> is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R<4> is SO2NR<7>R<8>; R<5> and R<6> are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R<7> and R<8>, together with the nitrogen atom to which they are attached, form a 4-R<10>-piperazinyl group; R<10> is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; Het is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, inter alia, male erectile dysfunction and female sexual dysfunction. |